• Tues news: Prostate cancer trials to watch. Merck’s subcutaneous Keytruda. Apellis sees positive in Astellas CRL. Future of Medicare price negotiations. JNJ psoriasis results. See more on our front page

Nominees for best AbbVie blunder in the last 10 years are…

Quote
anonymous said:
What about the huge influx of consultants, who have no prior drug development experience, are now teaching those in the fields for years about how to develop drugs, transform and innovate. They brand themselves problem solver and out of the box thinker. Well, it’s because they have never been in a box to know how a box actually work!
Click to expand...
 




No serious drug developer works here. Abbvie is a commercial powerhouse. The acquire assets in late stage and get them across the finish line and let their tremendous commercial execution takeover. The assets they acquire early never go anywhere once they enter the AbbVie machine. See Allergan for recent example what has actually progressed from the early stage over the past almost 5 yrs?

The consultants are needed to fix this mess and get the people who think they know what they are doing out of the way.
 




anonymous said:
No serious drug developer works here. Abbvie is a commercial powerhouse. The acquire assets in late stage and get them across the finish line and let their tremendous commercial execution takeover. The assets they acquire early never go anywhere once they enter the AbbVie machine. See Allergan for recent example what has actually progressed from the early stage over the past almost 5 yrs?

The consultants are needed to fix this mess and get the people who think they know what they are doing out of the way.
Click to expand...

Nailed it.
 




Hiring a District Sales Manager - Rheumatology - Illinois November 2023 with absolutely no sales experience! Her entire career has been in Marketing! Kraft Foods, Consumer Goods, etc. Unbelievable! Inconceivable!
 












Allergan Aesthetics leadership in a ring fence for too long. Case study for how you take a leading innovator, select the wrong talent to lead the go forward and then proceed to bleed money. This unit has become a bloated unproductive mess. It’s time to finally integrate R&D, so that new leadership can take over and what existing talent remains has a real chance to deliver new products. How many failures and bad decisions will be ‘forgiven’ before leaders are held accountable.
 




anonymous said:
Allergan Aesthetics leadership in a ring fence for too long. Case study for how you take a leading innovator, select the wrong talent to lead the go forward and then proceed to bleed money. This unit has become a bloated unproductive mess. It’s time to finally integrate R&D, so that new leadership can take over and what existing talent remains has a real chance to deliver new products. How many failures and bad decisions will be ‘forgiven’ before leaders are held accountable.
Click to expand...
They are always forgiven. Eventually, they passed the blame down to sales and smaller rolls. If you better this industry log it up in a certain disease state, there’s a very good chance that you’ve run into a lot of the same people. These leaders and higher positions seem to always land on their feet no matter how bad they perform. But as a sales rep, you have to explain away why you lost your position without saying that management was terrible or that your leader was unqualified for their position position. Make what you can of this industry. No one is here because they want to be, they probably just got here by luck And the monies been fairly decent. Collect your check, grow your network, and be ready to move on if need be.
 








Acquiring Allergan. It used to be a gem but nowadays it’s only losing market share. Competitive landscape has changed and the market is not as dynamic as in the past, inept leadership watching from the sidelines.
 
















anonymous said:
No serious drug developer works here. Abbvie is a commercial powerhouse. The acquire assets in late stage and get them across the finish line and let their tremendous commercial execution takeover. The assets they acquire early never go anywhere once they enter the AbbVie machine. See Allergan for recent example what has actually progressed from the early stage over the past almost 5 yrs?

The consultants are needed to fix this mess and get the people who think they know what they are doing out of the way.
Click to expand...
This is very true, and it makes me sad. It's a big difference from other big pharma companies. We do not appear to value science. It is a shame, since our commercialization engine is so powerful. We could be a top 3 pharma company if we were willing to make that investment.
 




anonymous said:
This is very true, and it makes me sad. It's a big difference from other big pharma companies. We do not appear to value science. It is a shame, since our commercialization engine is so powerful. We could be a top 3 pharma company if we were willing to make that investment.
Click to expand...
If my aunt had balls, she would be my uncle.
 




anonymous said:
This is very true, and it makes me sad. It's a big difference from other big pharma companies. We do not appear to value science. It is a shame, since our commercialization engine is so powerful. We could be a top 3 pharma company if we were willing to make that investment.
Click to expand...
Who would work on the innovation if the investment was made? Ding dong, preclinical device and the angry kangaroo? In life one must know their limitations and retaining competent drug developers is not a strength of this organization. I would argue increasing the R&D investment would be a serious blunder unless there is an entire new RDLT brought in. But Sleepy T’s flunkees are not going to turn this around.
 




anonymous said:
Sarah FM pushes the compliance envelope and it won’t take long before one of her subordinates turns her in and she goes down the same path as her buddy Britt. Bye Bye
Click to expand...
Have y'all not been paying attention? She got purged back in the summer and yet got a promotion to VP of Sales at Axsome. Bringing metrics and shady tactics to a whole new organization!
 












anonymous said:
Nicholas Donoghue… needs to go for Cerevel shit..
Click to expand...
Why? Why not the entire R&D due diligence team? Why not the AbbVie incompetent R&D leaders who devalued and eventually lost the CNS experts they acquired from Allergan who are responsible for their current commercial pipeline? Why not the decision makers who allow R&D to continue to fester in mediocrity (at best). Why not the legacy Allergan leaders who knew the space and the teams at other companies and didn’t advocate for say Karuna? Pretty sure a few people knew the former CEO and his track record in CNS.

ND is trying to fill these gaps but he cant do it alone. It’s a Phase 2 failure. This lies at the feet of R&D and a few commercial leaders who should have led.
 




Top Bottom
Back
Quote